Risultati per: Terapia del dolore da osteo-artropatie degenerative

This cohort study assesses residual mitral regurgitation and mitral gradient outcomes as well as clinical outcomes after transcatheter mitral valve repair in a registry of patients with moderate to severe or severe degenerative mitral regurgitation.

Può ridurre gli effetti collaterali rispetto alla radioterapia

Per esami pre natale. Appello dell’immunologo e di Zaccheddu.

Oggi Giornata mondiale; Fedemo, più risorse strutturali e umane

Progetto di musicoterapia con Allieve Santa Cecilia e Neuchatel

Più difese immunitarie, meno antidolorifici e ricoveri più brevi

Per immunoterapia più efficace. Int guida progetto internazionale

Ricorrendo a globuli bianchi di donatori sani

Ok Aifa rimborsabilità molecola, migliora probabilità guarigione

Approvato da Fda previene attacchi, riduce giorni d’uso farmaci

Introduction
Degenerative cervical myelopathy (DCM) is a common and disabling condition of symptomatic cervical spinal cord compression secondary to degenerative changes in spinal structures leading to a mechanical stress injury of the spinal cord. RECEDE-Myelopathy aims to test the disease-modulating activity of the phosphodiesterase 3/phosphodiesterase 4 inhibitor Ibudilast as an adjuvant to surgical decompression in DCM.

Methods and analysis
RECEDE-Myelopathy is a multicentre, double-blind, randomised, placebo-controlled trial. Participants will be randomised to receive either 60–100 mg Ibudilast or placebo starting within 10 weeks prior to surgery and continuing for 24 weeks after surgery for a maximum of 34 weeks. Adults with DCM, who have a modified Japanese Orthopaedic Association (mJOA) score 8–14 inclusive and are scheduled for their first decompressive surgery are eligible for inclusion. The coprimary endpoints are pain measured on a visual analogue scale and physical function measured by the mJOA score at 6 months after surgery. Clinical assessments will be undertaken preoperatively, postoperatively and 3, 6 and 12 months after surgery. We hypothesise that adjuvant therapy with Ibudilast leads to a meaningful and additional improvement in either pain or function, as compared with standard routine care.

Study design
Clinical trial protocol V.2.2 October 2020.

Ethics and dissemination
Ethical approval has been obtained from HRA—Wales.The results will be presented at an international and national scientific conferences and in a peer-reviewed journals.

Trial registration number
ISRCTN Number: ISRCTN16682024.

Dopo 6 settimane di discesa dei contagi. Decessi -18,4%, ricoveri +4%

La neoplasia che ha colpito il pianista Giovanni Allevi

Nel 2022 la Giornata Mondiale per la Sicurezza dei Pazienti è stata dedicata alla Sicurezza della terapia farmacologica. Ecco i risultati dell’iniziativa promossa dall’Italian Network For Safety in Healthcare in collaborazione con l’Istituto Mario Negri